Logo

UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Share this

UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Shots:

  • The approval is based on 3 P-III studies i.e.- BE VIVID- BE READY- BE SURE evaluating the efficacy & safety of bimekizumab vs PBO + ustekinumab- PBO- adalimumab in 1480 patients with a mod. to sev. PsO. The EC's approval is valid in 27 member states of the EU- Iceland- Liechtenstein & Norway
  • The studies met its co-primary EPs & 2EPs i.e.- 60% of patients achieved complete skin clearance @16wks. & clinical response was maintained for ~1yrs.- 90% improvement in PASI 90 & IGA response of clear or almost clear skin
  • The results from P-III BE READY & BE VIVID studies are published in The Lancet & P-III BE SURE study in NEJM. The therapy is currently under FDA & other countries’ review

Click hereRef: UCB | Image: Pharmaceutical Technology

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions